TIDMCIZ
RNS Number : 1630N
Cizzle Biotechnology Holdings PLC
30 May 2022
Cizzle Biotechnology Holdings Plc
("Cizzle Biotechnology", "Cizzle" or the "Company")
Results for the year ended 31 December 2021
Cizzle Biotechnology, the UK-based diagnostics developer, is
pleased to announce its audited results for the year ended 31
December 2021.
Chair's Statement
I am pleased to report on the Group's activities and results for
2021 during which we announced the acquisition of Cizzle
Biotechnology Limited ("CBL") on 14 May 2021 and admission to
trading on the London Stock Exchange by way of a Standard Listing,
raising proceeds of GBP2,200,000 before expenses from the issue of
new shares. We changed the company name from Bould Opportunities
plc to Cizzle Biotechnology Holdings plc to better reflect the
Group's ambitions to become a leading biotechnology business
focussed on early-stage cancer detection through the
commercialisation of its proprietary CIZ1B biomarker technology
developed by Professor Dawn Coverley and her team at the University
of York for the early detection of lung cancer.
The Group has made significant progress during 2021 and so far
in 2022. In addition to implementing our strategy to develop a
regulatory approved commercial, diagnostic laboratory immunoassay
for early-stage lung cancer, we have broadened our interests in the
detection of a range of other early-stage cancers, expanded our
potential customer base to include the pharmaceutical industry
through diagnostic tests that can help in the development of
personalised medicines, so called "companion diagnostics" and
secured royalty bearing rights to the sale of such drugs in the
longer term.
To achieve this we have entered into a number of strategic
supply agreements, extended our research and development programme
with the University of York, secured an important companion
diagnostic development project for autoimmune diseases worth up to
GBP1m with St George Street Capital ("SGSC") and invested in
royalty arrangements for their therapeutic asset (AZD1656) for the
potential treatment of inflammatory diseases, including those
linked with COVID 19.
The Group has also begun the process of selecting appropriate
industrial development and distribution partners that will
facilitate access to major markets globally and we are pleased to
announce a royalty bearing strategic partnership in China to help
address the country's challenge of reducing nearly 715,000 deaths
caused by lung cancer in 2020.
(Source:
https://www.statista.com/statistics/1053667/china-cancer-death-number-by-type/
).
Research and Development
The Group is developing a blood test for the early detection of
lung cancer. Its proof of concept prototype test is based on the
ability to detect a stable plasma biomarker, a variant of CIZ1
known as CIZ1B. CIZ1 is a naturally occurring cell nuclear protein
involved in DNA replication, and the targeted CIZ1B variant is
highly correlated with early stage lung cancer. Currently the
laboratory test developed by Professor Dawn Coverley at The
University of York, has been used to validate the use of CIZ1B to
detect lung cancer, and a proof of concept prototype test
developed, which is compatible with potential use within a hospital
laboratory setting.
In June 2021 we entered into a Collaboration Agreement with
FairJourney Biologics to develop proprietary antibodies. Along with
other key suppliers the Group expects to create a range of
monoclonal antibodies and reagents that are the foundation for
developing immunoassays, and in the future point of care tests not
only for early-stage lung cancer but potentially also for other
cancers with unmet clinical need.
In September 2021 we announced a new research agreement with The
University of York for developing our blood test for the early
detection of lung cancer, and potentially other forms of cancer. A
further new agreement was announced in April 2022 that extended
this work until June 2022.
A research and development agreement was finalised in October
2021 with "SGSC", the UK based biomedical charity to develop a
companion diagnostic test for autoimmune disease. Its aim is to
develop tests that will operate alongside SGSC's programme for the
development of therapeutic assets licensed to SGSC from one of the
world's largest pharmaceutical companies, Astra Zeneca. This seeks
to address unmet clinical needs in a variety of autoimmune diseases
which will significantly broaden the Company's product pipeline for
which SGSC will pay the Group GBP200,000 upfront on commencement of
the project and then further milestone payments totalling
GBP1m.
China
One of the target markets identified for the Group is in China
where we are aware there are serious challenges in being able to
detect cancer early, and there is a great need for screening and
diagnosing cancers among the Chinese population. Targeted testing
can improve timely access to cancer care and save lives. The Group
entered into a Memorandum of Understanding ("MOU") with the
International Co-innovation Centre for Advanced Medical Technology
("iCCAMT") and Shenzhen Intelliphecy Life Technologies Co. Ltd
("Intelliphecy") to develop and market the Group's proprietary
early lung cancer diagnostic tests based on the CIZ1B biomarker in
China.
In February 2022 a full commercial agreement was executed to
develop and market early lung cancer diagnostic tests in China.
This agreement will generate future revenues for the Group via a
10% royalty on the sales of all products and services using its
proprietary CIZ1B technology and from payment for monoclonal
antibodies and reagents.
iCCAMT, founded with German Medical Valley, Robert Bosch GmbH
and Sinopharm Group, aims to accelerate global med-tech innovation
in the Chinese market, by bringing together world leading
expertise. Intelliphecy is aiming to innovate technologies in the
hope to win the war against cancer.
USA
On 6 May 2022 the Group announced that it had signed a heads of
terms to partner with CorePath Laboratories (CorePath), a full
service cancer reference laboratory, to develop and offer its
proprietary early-stage lung cancer test throughout the USA. The
proposal is that the Group would receive a 15% royalty and royalty
sharing arrangements overall offering of products and services
using CIZ1B via CorePath in the USA.
Lung cancer is the leading cause of cancer death in the USA,
making up almost 25% of all cancer deaths. The American Cancer
Society's estimates for lung cancer in the USA for 2022 are:
- About 236,740 new cases of lung cancer annually and about
130 - 180 deaths from lung cancer each year (Source :
https://www.cancer.org/cancer/lung-cancer/about/key-statistics.html
); and
- Currently, there are no simple specific blood tests to
detect lung cancer early when targeted interventions
can improve timely access to cancer care and save lives.
Yet it is estimated that about 8 million Americans qualify
as high risk of lung cancer and are recommended to receive
annual screening with low-dose CT scans and if half of
these high risk individuals were screened, over 12,000
lung cancer deaths could be prevented (Source: Cheung
LC, Katki HA, Charurvedi AK, Jemal A, Berg CD. Preventing
Lung Cancer Mortality by Computed Tomography Screening:
The Effect of Risk-Based Versus U.S. Preventative Services
Task Force Eligibility Criteria, 2005-2015. Anals of
Internal Medicine. 2018; 168(3):229-32. Doi: 10.7326/M17-2067).
Royalty Investment in AZD1656
In September 2021 the Group entered into a royalty sharing
agreement with SGSC to grant the Group potential royalty payments
from the commercialisation of SGSC's therapeutic asset AZD1656 of
up to GBP5m, plus potentially further payments from the use of a
companion diagnostic. During the year the Group paid a total of
GBP0.2m for this investment.
This supports the strategy of building a portfolio of early
cancer detection tests, companion diagnostics and royalty bearing
stakes in significant drug assets. SGSC has reported positive
results from its ARCADIA clinical trial for diabetes patients with
COVID19 and have indicated this may be through the regulation of
the patients' immune system (via controlling Regulatory T Cells or
"Tregs"). Tregs act to suppress immune response and combat damaging
cells potentially reducing serious cardiovascular disease, and also
lung diseases that are linked with the development of lung
cancer.
In February 2022 the Group announced a further royalty deal in
Inflammatory Pulmonary and Cardiovascular diseases with Conduit
Pharmaceuticals Ltd ("Conduit") and SGSC to acquire an additional
5% economic interest in the commercialisation of the AZD 1656 asset
or such other assets being developed by Conduit or SGSC to treat
inflammatory pulmonary and cardiovascular disease. Under the
agreement the Group will receive 5% of all sums received by SGSC
pursuant to any AstraZeneca ("AZ") commercialisation or sub-licence
commercialisation of the AZD 1656 asset in inflammatory pulmonary
and cardiovascular diseases, after the deduction of certain sums.
The consideration due to SGSC is GBP1.88m with the initial
consideration of GBP1m being settled through the issue of
25,000,000 new ordinary shares at a price of 4.0p per share, which
was a premium of 56.9% to the Company's closing mid-market price of
2.55p on 11 February 2022. The remaining consideration of GBP0.88m
will be payable in new ordinary shares at 4.0p per share, on the
earlier of receiving shareholder approval to issue the shares or
the first anniversary of completion.
Financial overview
Due to reverse acquisition accounting principles, which are
explained in more detail in Note 3 to the financial statements,
these consolidated financial statements represent a continuation of
the consolidated statements of Cizzle Biotechnology Holdings PLC
("the Company") and its subsidiaries (together referred to as "the
Group") and include:
- The assets and liabilities of CBL at their pre-acquisition
carrying value amounts and the results for all periods
reported: and
- The assets and liabilities of the Company as at 14 May
2021 and its results from the date of reverse acquisition
on 14 May 2021 to 31 December 2021.
As the new Group was not in existence in 2020 the comparative
results under reverse acquisition rules are those of the existing
company, CBL, that effectively completed the acquisition. The
financial results for the period to 31 December 2021 are summarized
below:
- Corporate expenses, before share option charge and exceptional
items: GBP552,000 (2020 CBL: GBP14,000);
- Share option charge: GBP299,000 (2020 CBL: GBPNil)
- Exceptional corporate expenses relating to the acquisition:
GBP3,117,000 (2020 CBL: GBPNil) which include transaction
costs of GBP303,000 and a non-cash share-based expense
of GBP2,804,000 (explained in Notes 3 and 5);
- Total comprehensive loss: GBP 3,921,000 (2020 CBL Loss
GBP 14,000); and
- Loss per share 2.4 p (2020 CBL Loss 2.8) p.
Allan Syms
Executive Chair
Enquiries:
Cizzle Biotechnology Holdings Via IFC Advisory
plc
Allan Syms (Executive Chairman)
Allenby Capital Limited +44(0) 20 33285656
John Depasquale
Alex Brearley
Novum Securities Limited +44(0) 20 7399 9400
Colin Rowbury
Jon Bellis
IFC Advisory Limited +44(0) 20 3934 6630
Tim Metcalfe cizzle@investor-focus.co.uk
Florence Chandler
Notes to Editors:
About Cizzle Biotechnology
Cizzle Biotechnology is developing a blood test for the early
detection of lung cancer. Cizzle Biotechnology is a spin- out from
the University of York, founded in 2006 around the work of
Professor Coverley and colleagues . Its proof-of-concept prototype
test is based on the ability to detect a stable plasma biomarker, a
variant of CIZ1 known as CIZ1B. CIZ1 is a naturally occurring cell
nuclear protein involved in DNA replication, and the targeted CIZ1B
variant is highly correlated with early-stage lung cancer.
For more information, please see
https://cizzlebiotechnology.com
You can also follow the Company through its twitter account
@CizzlePlc and on LinkedIn.
Consolidated Statement of Comprehensive Income
for the period year ended 31 December 2021
Notes
Group CBL
Year ended Year ended
31 December 31 December
2021 2020
GBP'000 GBP'000
------------------------------------------- ------ ------------------------------- ----------------
Revenue - -
Cost of sales - -
------------------------------------------- ------ ------------------------------- ----------------
Gross profit - -
Administrative expenses
* on-going administrative costs 6 (552) (14)
* share option charge 6 (299) -
* transaction costs 6 (303) -
* reverse acquisition expenses 6 (2,804) -
------------------------------------------- ------ ------------------------------- ----------------
Total administrative expenses (3,958) (14)
Operating (loss) and (loss) before
income tax (3,958) (14)
Income tax 9 37 -
------------------------------------------- ------ ------------------------------------ -----------
Loss and total comprehensive income
for the year
attributable to the equity shareholders
of the parent (3,921) (14)
------------------------------------------- -------------- ---------------------------- -----------
Earnings per ordinary share (pence)
attributable to the equity shareholders:
Continued operations basic and diluted 10 (2.4p) (2.8p)
Earnings per ordinary share (pence)
attributable to
the equity shareholders of the
parent 10 (2.4p) (2.8p)
The Company has elected to take the exemption provided under
section 408, Companies Act 2006 from presenting the Company
statement of comprehensive income.
The notes are an integral part of these financial
statements.
Consolidated Statement of Financial Position
A s at 31 December 2021
Notes Group CBL
2021 2020
GBP'000 GBP'000
---------------------------------- ----- -------- --------
Non-current assets
Intangible asset 11 200 -
Tangible assets 11 - -
200 -
Current assets
Trade and other receivables 12 80 3
Cash and cash equivalents 13 875 7
---------------------------------- ----- -------- --------
955 10
---------------------------------- ----- -------- --------
Total assets 1,155 10
---------------------------------- ----- -------- --------
Equity
Capital and reserves attributable
to equity holders of the company
Ordinary shares 14 3,493 3
Share premium 32,566 1,585
Reverse acquisition reserve (40,021) -
Share capital reduction reserve 10,081 -
Share option reserve 335 -
Retained losses (5,517) (1,596)
---------------------------------- ----- -------- --------
Total equity 937 (8)
---------------------------------- ----- -------- --------
Liabilities
Current liabilities
Trade and other payables 15 218 8
Borrowings - 10
Total liabilities 218 18
---------------------------------- ----- -------- --------
Total equity and liabilities 1,155 10
---------------------------------- ----- -------- --------
The notes are an integral part of these financial
statements.
The financial statements were approved and authorised for issue
by the board on 30 May 2022 and were signed on its behalf by:
Nigel Lee
Director
Company Statement of Financial Position
A s at 31 December 2021
Notes 2021 2020
GBP'000 GBP'000
---------------------------------- ----- -------- --------
Non-current assets
Intangible asset 11 200
Investments 11 21,803 -
22,003 -
Current assets
Trade and other receivables 12 241 6
Cash and cash equivalents 13 848 84
1,089 90
---------------------------------- ----- -------- --------
Total assets 23,092 90
---------------------------------- ----- -------- --------
Equity
Capital and reserves attributable
to equity holders of the company
Ordinary shares 14 3,493 3,470
Share premium 32,566 8,852
Share capital reduction reserve 10,081 10,081
Share option reserve 335 -
Accumulated losses (23,516) (22,371)
---------------------------------- ----- -------- --------
Total equity 22,959 32
---------------------------------- ----- -------- --------
Liabilities
Current liabilities
Trade and other payables 15 133 58
Total liabilities 133 58
---------------------------------- ----- -------- --------
Total equity and liabilities 23,092 90
---------------------------------- ----- -------- --------
The notes are an integral part of these financial statements.
The loss for the year of the Company was GBP1,145,000 (2020: loss
of GBP306,000).
The financial statements were approved and authorised for issue
by the board on 30 May 2022 and were signed on its behalf by:
Nigel Lee
Director
Consolidated Statement of Cash Flows for the year ended 31
December 2021
Notes Group CBL
2021 2020
GBP'000 GBP'000
-------------------------------------------- ------ -------- --------
Cash flows from operating activities
Operating (loss) before tax (3,958) (14)
Adjustment for:
Reverse acquisition expense 3,6 2,804 -
Share option charge 299 -
Transaction costs settled through
share issue 32 -
Share based payment to former director 11 -
-------------------------------------------- ------ -------- --------
Operating cash flow before working
capital movements (812) (14)
Decrease in trade and other receivables 12 7 -
Decrease in trade and other payables 15 (204) (2)
-------------------------------------------- ------ -------- --------
Net cash used in operating activities (1,009) (16)
-------------------------------------------- ------ -------- --------
Cash flows from investing activities
Cash acquired on acquisition of subsidiary 46 -
Purchase of investment in intangible
assets 11 (200) -
-------------------------------------------- ------ -------- --------
Net cash used in investing activities (154) -
-------------------------------------------- ------ -------- --------
Cash flows from financing activities
Proceeds from the issue of ordinary
shares (net of issue costs) 14 2,041 -
Borrowings received - 10
Borrowings repaid (10) -
Net cash generated from financing
activities 2,031 10
-------------------------------------------- ------ -------- --------
Net increase / (decrease) in cash
and cash equivalents 868 (6)
Cash and cash equivalents at the
start of the year 13 7 13
-------------------------------------------- ------ -------- --------
Cash and cash equivalents at the
end of the year 13 875 7
-------------------------------------------- ------ -------- --------
The notes are an integral part of these financial
statements.
Company Statement of Cash Flows for the year ended 31 December
2021
Notes 2021 2020
GBP'000 GBP'000
--------------------------------------- ------ -------- --------
Cash flows from operating activities
Loss before tax (1,145) (306)
Share option charge 299 -
Transaction costs settled through
share issue 32
--------------------------------------- ------ -------- --------
Operating cash flow before working
capital movements (814) (306)
Change in trade and other receivables 12 (19) 25
Change in trade and other payables 15 75 (13)
--------------------------------------- ------ -------- --------
Net cash used in operating activities (758) (294)
--------------------------------------- ------ -------- --------
Cash flows from investing activities
Purchase of investment in intangible
assets (200) -
Investment in subsidiary company 11 (103) -
Change in intra group funding (216) -
--------------------------------------- ------ -------- --------
Net cash used in investing activities (519) -
--------------------------------------- ------ -------- --------
Cash flows from financing activities
Proceeds from the issue of ordinary
shares (net of issue costs) 14 2,041 -
Net cash generated from financing
activities 2,041 -
--------------------------------------- ------ -------- --------
Net increase / (decrease) in cash
and cash equivalents 764 (294)
Cash and cash equivalents at the
start of the year 13 84 378
--------------------------------------- ------ -------- --------
Cash and cash equivalents at the
end of the year 13 848 84
--------------------------------------- ------ -------- --------
The notes are an integral part of these financial
statements.
Group statement of Changes in Equity
for the year ended 31 December 2021
Ordinary Capital Share Reverse
Share Share Redemption Option Acquisition Retained
Group Capital Premium Reserve Reserve Reserve Losses Total
GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000
At 1 January 2021 3 1,585 - - - (1,596) (8)
Issue of shares - 11 - - - - 11
Transfer to reverse
acquisition
reserve (3) (1,596) - - 1,599 - -
Recognition of plc equity
at acquisition date 3,470 8,852 10,081 - (22,621) - (218)
Issue of shares for
acquisition
of subsidiary 21 21,679 - - (21,803) - (103)
Reverse acquisition
expense - - - - 2,804 - 2,804
Issue of shares for cash 2 2,198 - - - - 2,200
Issue of shares in
settlement
of fees - 32 - - - - 32
Issue of warrants - (36) - 36 - - -
Cost of share issue - (159) - - - - (159)
Share option charge - - - 299 - - 299
-------- -------- ------------ -------- -------------------- --------- --------
3,493 32,566 10,081 335 (40,021) (1,596) 4,858
Comprehensive Loss for
the year - - - - - (3,921) (3,921)
At 31 December 2021 3,493 32,566 10,081 335 (40,021) (5,517) 937
-------- -------- ------------ -------- -------------------- --------- --------
For the year ended 31 December 2020
Ordinary
Share Share Retained
CBL Capital Premium Losses Total
GBP'000 GBP'000 GBP'000 GBP'000
At 1 January 2020 3 1,585 (1,582) 6
Comprehensive loss for
the year - - (14) (14)
At 31 December 2020 3 1,585 (1,596) (8)
----------- ---------- ----------- ---------
Company statement of Changes in Equity
for the year ended 31 December 2021
Share
Ordinary Share capital Share
Share premium reduction option Retained
Capital reserve reserve Losses Total
GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000
At 1 January 2020 3,470 8,852 10,081 - (22,065) 338
Comprehensive Loss for
the year - - - - (306) (306)
--------- --------- ----------- --------- --------- ---------
At 31 December 2020 3,470 8,852 10,081 - (22,371) 32
Issue of shares for acquisition
of subsidiary 21 21,679 - - - 21,700
Issue of shares for cash 2 2,198 - - - 2,200
Issue of shares in settlement
of fees - 32 - - - 32
Cost of share issue - (159) - - - (159)
Issue of warrants - (36) - 36 - -
Share option charge - - - 299 - 299
--------- --------- ----------- --------- --------- ---------
3,493 32,566 10,081 335 (22,371) 24,104
Comprehensive Loss for
the year - - - - (1,145) (1,145)
At 31 December 2021 3,493 32,566 10,081 335 (23,516) 22,959
--------- --------- ----------- --------- --------- ---------
The notes are an integral part of these financial
statements.
Notes to the financial statements for the year ended 31 December
2021
1 General information
Cizzle Biotechnology Holdings PLC ("the Company" of "the Group")
(formerly Bould Opportunities PLC) is a public limited company with
its shares traded on the Standard Listing of the London Stock
Exchange. On 14 May 2021 the Company acquired through a share for
share exchange the entire share capital of Cizzle Biotechnology
Limited. The Company is a holding company of a group of companies
("the Group") whose principal activity is the early detection of
lung cancer via the development of an immunoassay test for the
CIZ1B biomarker.
The directors consider there to be no ultimate controlling
shareholder of the Company.
The address of the registered office is 6(th) Floor, 60
Gracechurch Street, London, EC3V 0HR and the registered number of
the Company is 06133765.
2 Accounting policies
The principal accounting policies applied in the preparation of
these financial statements are set out below. These policies have
been consistently applied to all the years presented, unless
otherwise stated.
2.1 Basis of preparation
The financial statements of Cizzle Biotechnology Holdings PLC
("the Company") including subsidiary undertakings (together
referred to as "the Group") have been prepared in accordance with
UK-adopted international accounting standards, and the Companies
Act 2006 on a historical cost basis.
The preparation of financial statements in conformity with IFRS
requires the use of certain critical accounting estimates. It also
requires management to exercise its judgement in the process of
applying the Company's accounting policies. The areas involving a
higher degree of judgement or complexity, or areas where
assumptions and estimates are significant to the financial
statements are disclosed in Note 4.
The results for the year ended 31 December 2021 are the Group
results following the acquisition of Cizzle Biotechnology Limited
("CBL") on 14 May 2021. The results for the comparative period to
31 December 2020 are the results of CBL prior to the creation of
the new Group.
(a) New standards and interpretations
The IASB and IFRS Interpretations Committee have issued the
following standards and interpretations with an effective date of
implementation of 1 January 2021.
i) New standards and amendments - applicable 1 January 2021
The following standard and interpretations apply for the first
time to financial reporting periods commencing on or after 1
January 2021:
Effective Impact
for accounting
periods beginning
on or after
Interest rate benchmark reform - Amendments to 1 January None
IFRS 17 "Insurance Contracts" 2021
Interest rate benchmark reform - Amendments to 1 January None
IFRS 16 "Leases" 2021
Interest rate benchmark reform - Amendments to 1 January None
IFRS 9 "Financial Instruments" 2021
Interest rate benchmark reform - Amendments to 1 January None
IAS 39 "Financial Instruments: Recognition and 2021
Measurement"
Interest rate benchmark reform - Amendments to 1 January None
IFRS 7 "Financial Instruments: Disclosures" 2021
ii) Forthcoming requirements
As at 31 December 2021, the following standards and
interpretations had been issued but were not mandatory for annual
reporting periods ending on 31 December 2021 and not early
adopted.
Effective Impact
for accounting
periods beginning
on or after
COVID-19 related Rent Concessions - Amendments 1 March 2021 None
to IFRS 16
Income Taxes - Deferred tax amendments to IAS 1 May 2021 None
12
Property, Plant and Equipment: Proceeds before 1 January None
intended use - Amendments to IAS 16 2022
Reference to the Conceptual Framework - Amendments 1 January None
to IFRS 3 2022
Onerous Contracts: Cost of Fulfilling a Contract 1 January None
- Amendments to IAS 37 2022
Annual Improvements to IFRS Standards 2018-2020 1 January None
2022
Classification of Liabilities as Current or Non-current 1 January None
- Amendments to IAS 1 2022
2.2 Going concern
The Directors have adopted the going concern basis in preparing
the financial statements for the year to 31 December 2021. In
reaching this conclusion, the Directors have considered current
trading and the current and projected funding position for the
period of just over 12 months from the date of approval of the
financial statements through to 30 June 2023. The Company, as
anticipated in the Company's Prospectus announced on 23 April 2021,
will need to generate finance through equity or debt in order to
meet its committed liabilities as they fall due for the foreseeable
future and progress its planned product research and development
activities. The auditors have made reference to a material
uncertainty in respect of going concern in their audit report. The
assessment of the COVID-19 situation continues to be monitored by
the directors. It's impact to date on the Group's operations has
been minimal.
Current funding
The Company's cash balance as at 31 December 2021 was GBP875,000
and there were no borrowing facilities at that date. On 14 May 2021
the Company raised GBP2,200,000, before share issue costs, through
the placing of new ordinary shares in conjunction with the
admission of its shares to trading on the London Stock Exchange by
way of a Standard Listing.
Conclusion
After taking account of the Company's current funding position,
its cash flow projections and the risks and uncertainties
associated with these, the directors have a reasonable expectation
that the Company has access to adequate resources to continue in
operational existence for the foreseeable future. For these reasons
they continue to prepare the financial statements on a going
concern basis. These financial statements do not include any
adjustments that would result from the going concern basis of
preparation being inappropriate.
2.3 Segmental reporting
IFRS 8 requires that segmental information be disclosed on the
basis of information reported to the chief operating decision
maker. The Company considers that the role of chief operating
decision maker is performed by the Company's Board of Directors.
The Group's only business activity and single segment is the
development of tests for the early detection of lung cancer.
2.4 Foreign currency translation
The functional currency of the Company is Sterling which is also
the presentational currency of the financial statements. Foreign
currency assets and liabilities are converted into Sterling at the
rates of exchange ruling at the end of the financial year. Foreign
currency transactions are translated into the functional currency
using the exchange rates prevailing at the dates of the
transactions. Foreign exchange gains and losses resulting from the
settlement of such transactions and from the translation at year
end exchange rates of monetary assets and liabilities denominated
in foreign currencies are recognised in the statement of
comprehensive income.
2.5 Non-Current assets
Investments in intangible assets and subsidiaries are stated at
cost less accumulated impairment. Plant and equipment are stated at
costs less accumulated depreciation and any accumulated impairment
losses. Depreciation is charged to write off costs less estimated
residual values on a straight-line basis over their estimated
useful lives. Estimated useful lives are reviewed each year and
amended if necessary.
2.6 Cash and cash equivalents
Cash and cash equivalents include cash in hand, deposits held at
call with banks and other short-term highly liquid investments,
with original maturities of three months or less.
2.7 Share capital
Ordinary shares are classified as equity. Incremental costs
directly attributable to the issue of new shares or options are
shown in equity as a deduction, net of tax, from the proceeds.
2.8 Current and deferred income tax
Current income tax is calculated on the basis of the tax laws
enacted or substantively enacted at the statement of financial
position date in the countries where the Company's subsidiaries and
associates operate and generate taxable income. Management
periodically evaluates positions taken in tax returns with respect
to situations in which applicable tax regulation is subject to
interpretation and establishes provisions where appropriate on the
basis of amounts expected to be paid to the tax authorities.
Deferred income tax is provided in full, using the liability
method, on temporary differences arising between the tax bases of
assets and liabilities and their carrying amounts in the financial
statements. However, deferred income tax is not accounted for if it
arises from initial recognition of an asset or liability in a
transaction other than a business combination that at the time of
the transaction affects neither accounting nor taxable profit nor
loss. Deferred income tax is determined using tax rates (and laws)
that have been enacted or substantively enacted by the statement of
financial position date and are expected to apply when the related
deferred income tax asset is realised or the deferred income tax
liability is settled. Deferred income tax assets are recognised to
the extent that it is probable that future taxable profit will be
available against which the temporary differences can be
utilised.
2.9 Share based payments
The Company operates an equity-settled, share-based compensation
plan. The fair value of the employee services received in exchange
for the grant of the options is recognised as an expense and
credited to the share option reserve within equity. The total
amount to be expensed over the vesting period is determined by
reference to the fair value of the options granted, excluding the
impact of any non-market vesting conditions (for example,
profitability and sales growth targets). Options that lapse before
vesting are credited back to income. The proceeds received net of
any directly attributable transaction costs are credited to share
capital (nominal value) and, if applicable, share premium when the
options are exercised.
2.10 Financial instruments
i) Financial assets
The Company classifies its financial assets in the following
measurement categories:
-- those to be measured subsequently at fair value through
profit or loss; and
-- those to be measured at amortised cost.
The classification depends on the business model for managing
the financial assets and the contracted terms of the cash flows.
Financial assets are classified as at amortised cost only if both
of the following criteria are met:
-- the asset is held within a business model whose objective
is to collect contracted cash flows; and
-- the contractual terms give rise to cash flows that are
solely payments of principal and interest.
Financial assets, including trade and other receivables and cash
and bank balances, are initially recognised at transaction price,
unless the arrangement constitutes a financing transaction, where
the transaction is measured at the present value of the future
receipts discounted at a market rate of interest.
Such assets are subsequently carried at amortised cost using the
effective interest method.
At the end of each reporting period financial assets measured at
amortised cost are assessed for objective evidence of impairment.
If an asset is impaired the impairment loss is the difference
between the carrying amount and the present value of the estimated
cash flows discounted at the asset's original effective interest
rate. The impairment loss is recognised in the consolidated income
statement.
The Company applies the simplified approach in calculating the
expected credit losses (ECLs) as permitted by IFRS 9. Changes in
credit risk is not tracked but instead a loss allowance is
recognised at each reporting date based on the financial asset's
lifetime ECL.
If there is a decrease in the impairment loss arising from an
event occurring after the impairment was recognised the impairment
is reversed. The reversal is such that the current carrying amount
does not exceed what the carrying amount would have been had the
impairment not previously been recognised. The impairment reversal
is recognised in the consolidated income statement.
Financial assets are derecognised when (a) the contractual
rights to the cash flows from the asset expire or are settled, or
(b) substantially all the risks and rewards of the ownership of the
asset are transferred to another party or (c) despite having
retained some significant risks and rewards of ownership, control
of the asset has been transferred to another party who has the
practical ability to unilaterally sell the asset to an unrelated
third party without imposing additional restrictions
ii) Financial liabilities
Basic financial liabilities, being trade and other payables, are
initially recognised at transaction price, unless the arrangement
constitutes a financing transaction, where the debt instrument is
measured at the present value of the future receipts discounted at
a market rate of interest.
Trade payables are obligations to pay for goods or services that
have been acquired in the ordinary course of business from
suppliers. Accounts payable are classified as current liabilities
if payment is due within one year or less. If not, they are
presented as non-current liabilities. Trade payables are recognised
initially at transaction price and subsequently measured at
amortised cost using the effective interest method.
Financial liabilities are derecognised when the liability is
extinguished, that is when the contractual obligation is
discharged, cancelled or expires. The Company does not hold or
issue derivative financial instruments.
iii) Offsetting
Financial assets and liabilities are offset and the net amounts
presented in the financial statements when there is an enforceable
right to set off the recognised amounts and there is an intention
to settle on a net basis or to realise the asset and settle to
liability simultaneously.
2.11 Pensions
For defined contribution schemes the amount charged to the
statement of comprehensive income is the contribution payable in
the year. Differences between the contributions payable in the year
and contributions actually paid are shown either as accruals or
prepayments.
2.12 Exceptional items
The Company has separately identified certain net expenses that
are exceptional by either their size or the fact that they do not
normally occur in the Company's normal course of business. Such
items are recorded separately in the Statement of Comprehensive
Income and are explained further in Note 6.
3 Reverse acquisition
On 14 May 2021 the Company acquired through a share for share
exchange the entire share capital of CBL whose principal activity
is the early detection of lung cancer through the development of
tests to detect CIZ1B variant protein.
Although the transaction resulted in CBL becoming a wholly owned
subsidiary of the Company, the transaction constitutes a reverse
acquisition as the previous shareholders of CBL own a substantial
majority of the shares of the Company.
In substance the shareholders of CBL acquired a controlling
interest in the Company and the transaction has therefore been
accounted for as a reverse acquisition. As the Company's activities
prior to the acquisition were purely the maintenance of the AIM
listing, acquiring CBL and raising equity finance to provide the
required funding for the operations of the acquisition means it did
not meet the definition of a business combination in accordance
with IFRS 3.
Accordingly, this reverse acquisition does not constitute a
business combination and was accounted for in accordance with IFRS
2 "Share-based Payments" and associated IFRIC guidance. Although
the reverse acquisition is not a business combination, the Company
has become a legal parent and is required to apply IFRS 10 and
prepare consolidated financial statements. The directors have
prepared these financial statements using the reverse acquisition
methodology, but rather than recognise goodwill, the difference
between the equity value given up by the CBL shareholders is
charged to the statement of comprehensive income as a share-based
payment on reverse acquisition, and represents in substance the
cost of acquiring a quoted company.
In accordance with the reverse acquisition principles, these
consolidated financial statements represent a continuation of the
consolidated statements of Cizzle Biotechnology Holdings Plc and
its subsidiaries and include:
- The assets and liabilities of CBL at their pre-acquisition
carrying value amounts and the results for all periods reported;
and
- The assets and liabilities of the Company as at 14 May 2021
and its results from the date of reverse acquisition (14 May 2021
to 31 December 2021).
On 14 May 2021 the Company issued 206,310,903 ordinary shares to
acquire the 313,932 ordinary shares of CBL Limited. At 14 May 2021
the valuation of the investment in CBL was GBP21,700,000.
Because the legal subsidiary, CBL, was treated on consolidation
as the accounting acquirer and the legal parent company, Cizzle
Biotechnology Holdings Plc, was treated as an accounting
subsidiary, the fair value of the shares deemed to be issued by CBL
was calculated at GBP2,587,000 based on an assessment of the
purchase consideration for a 100% holding of Cizzle Biotechnology
Holdings plc.
The fair value of the net liabilities of Cizzle Biotechnology
Holdings Plc at acquisition was as follows:
GBP'000
Cash and cash equivalents 46
Other assets 47
Liabilities (310)
--------
Net (Liabilities) (217)
--------
The difference between the deemed cost of GBP2,587,000 and the
fair value of the net liabilities noted above of GBP(217,000)
resulted in GBP2,804,000 being expensed as "reverse acquisition
expenses" in accordance with IFRS2, Share- based Payments,
reflecting the economic cost to CBL shareholders of acquiring a
quoted entity.
The reverse acquisition reserve which arose from the reverse
takeover is made up as follows:
GBP'000
Pre-acquisition equity(1) (22,621)
CBL share capital at acquisition(2) 1,599
Investment in CBL(3) (21,803)
Reverse acquisition expense(4) 2,804
---------
(40,021)
---------
1. Pre-acquisition equity of Cizzle Biotechnology Holdings
PLC at 14 May 2021.
2. CBL had issued share capital and share premium of GBP1,599,000.
As these financial statements represent the capital structure
of the legal parent entity, the equity of CBL is eliminated.
3. The value of the shares issued by the Company in exchange
for the entire share capital of CBL plus stamp duty expenses.
4. The reverse acquisition expense represents the difference
between the value of the equity issued by the Company,
and the deemed consideration given by CBL to the Group.
Recognition of pre-acquisition equity of Cizzle Biotechnology
Holdings PLC at 14 May 2021.
CBL had issued share capital and share premium of GBP1,599,000.
As these financial statements represent the capital structure of
the legal parent entity, the equity of CBL is eliminated.
The value of the shares issued by the Company in exchange for
the entire share capital of CBL plus stamp duty expenses. The above
entry is required to eliminate the balance sheet impact of this
transaction.
The reverse acquisition expense represents the difference
between the value of the equity issued by the Company, and the
deemed consideration given by CBL to the Group.
4 Financial risk
The Group's principal risk factors are as follows:
4.1 Capital risk management
The Company monitors capital which comprises all components of
equity (i.e. share capital, share premium, capital reduction
reserve, share option reserve, and retained earnings/losses). Note
22 describes how capital is managed in respect of the debt to
equity ratio.
4.2 Financial risk factors
The Group's operations exposed it to a variety of financial
risks that had included the effects of credit risk, liquidity risk
and interest rate risk. The Company had in place a risk management
programme that attempted to limit the adverse effects on the
financial performance of the Company by monitoring levels of debt
finance and the related finance costs. The Company did not use
derivative financial instruments to manage interest rate costs and
as such, no hedge accounting was applied.
Given the size of the Company, the directors did not delegate
the responsibility of monitoring financial risk management to a
sub-committee of the Board. The policies set by the board of
directors were implemented by the Company's finance department.
a) Credit risk
The Company's credit risk was primarily attributable to
its trade receivables balance. The amounts presented in
the statement of financial position are net of allowances
for impairment.
b) Liquidity risk
L iquidity risk was the risk that an entity will encounter
difficulty in meeting obligations associated with financial
liabilities. The Company's financial liabilities included
its trade and other payables shown in Note 15.
c) Interest rate cash flow risk
The Company had interest-bearing assets. Interest bearing
assets comprised only cash balances, which earned interest
at floating rates.
5 Critical accounting estimates and judgements
In the preparation of the financial statements the directors
must make estimates and assumptions that affect the asset and
liability items and revenue and expense amounts recorded in the
financial statements. These estimates are based on historical
experience and various other assumptions that the Board believes
are reasonable under the circumstances. The results of this form
the basis for making judgements about the carrying value of assets
and liabilities that are not readily available from other
sources.
a) Accounting judgement
There were no judgments made.
b) Accounting estimate
Share based payments
See Note 14 which explains the methods used to estimate the fair
value of share options granted.
6 Operating expenses
Group CBL
2021 2020
GBP'000 GBP'000
Research and development 161 -
Professional advisers 89 -
Staff costs 88 -
Intellectual property renewal fees 57 14
Regulatory fees 53 -
Share based payment 37 -
Audit fees (Note 7) 27 -
Other expenditure 40 -
On-going administrative costs 552 14
Share option charge 299 -
Reverse acquisition expense 2,804 -
Transaction costs - IPO and reverse
acquisition 303
------------------------------------- --------- ---------
Total administrative expenses 3,958 14
------------------------------------- --------- ---------
7 Auditor's remuneration
Group CBL
2021 2020
GBP'000 GBP'000
------------------------------------------------ --------- ---------
Fees payable to the Company's auditor for 27 -
the audit of the Group, Company and subsidiary
financial statements
Non-audit services - reporting accountant 38 -
for IPO
------------------------------------------------ --------- ---------
65 -
------------------------------------------------ --------- ---------
8 Directors' emoluments
Group CBL Company Company
2021 2020 2021 2020
GBP'000 GBP'000 GBP'000 GBP'000
----------------------- --------- --------- --------- ---------
Wages and salaries 125 - 105 80
Social Security Costs 10 - 11 6
Pension Contributions 3 - 2 -
Share based payments 299 - 299 -
----------------------- --------- --------- --------- ---------
437 - 417 86
----------------------- --------- --------- --------- ---------
The Group does not have any employees other than the directors.
The average number of directors during the year was 4 (CBL 2020:
2).
9 Income tax credit
The tax credit for the year was as follows:
Group CBL
2021 2020
GBP'000 GBP'000
------------------------------------- --------- ---------
Research and development tax credits (37) -
------------------------------------- --------- ---------
(37) -
------------------------------------- --------- ---------
The tax on the Group's loss before tax differs from the
theoretical amount that would arise using the tax rate applicable
to the losses of the group (2020: CBL) as follows:
Group CBL
2021 2020
GBP'000 GBP'000
----------------------------------------------- --------- ---------
Loss before tax on continuing operations (3,958) -
----------------------------------------------- --------- ---------
Tax calculated at the domestic rate applicable (752) -
of 19% (2020: 19%)
Expenses not deductible for tax purposes 590 -
Tax losses for which no deferred tax credit 162 -
was recognised
Research and development tax credit (37) -
----------------------------------------------- --------- ---------
Total income tax credit (37) -
----------------------------------------------- --------- ---------
10 Earnings per share
Basic loss per share
Group CBL
2021 2020
-------------------------------------------- --------------- ------------
Loss for the year (GBP3,921,000) (GBP14,000)
-------------------------------------------- --------------- ------------
Weighted average number of ordinary shares 160,516,450 493,844
-------------------------------------------- --------------- ------------
Basic loss per share (2.4p) (2.8p)
-------------------------------------------- --------------- ------------
The basic loss per share is derived by dividing the loss for the
period attributable to ordinary shareholders by the weighted
average number of shares in issue. The weighted average number of
shares is adjusted for the impact of the reverse acquisition as
follows:
- Prior to the reverse acquisition, the number of shares
is based on CBL, adjusted using the share exchange ratio
arising on the reverse acquisition; and
- From the date of the reverse acquisition, the number of
share is based on the Company.
Diluted earnings per share is calculated by dividing the loss
attributable to ordinary shareholders by the weighted average
number of ordinary shares outstanding after adjusting these amounts
for the effects of dilutive potential ordinary shares. As the
results for the years ended 31 December 2021 and 31 December 2020
are a loss, any exercise of share options would have an
anti-dilutive effect on earnings per share. Consequently, earnings
per share and diluted earnings per share are the same and the
calculation has not been included.
As at 31 December 2021, there were share options outstanding
over 23,432,041 shares (CBL 2020: 14,928,864 shares), which could
potentially have a dilutive impact in the future.
11 Non- Current assets
Group CBL Company Company
2021 2020 2021 2020
GBP'000 GBP'000 GBP'000 GBP'000
--------------------------------------- --------- --------- --------- ---------
Investment in subsidiary undertakings - - 21,803 -
Intangible assets 200 - 200 -
Tangible assets - - - -
--------------------------------------- --------- --------- --------- ---------
Total investments 200 - 22,003 -
--------------------------------------- --------- --------- --------- ---------
a. Investments in subsidiary undertakings - Company
2021 2020
GBP'000 GBP'000
---------------------------- --------- ---------
Opening balance - -
Acquisition during the year 21,803 -
---------------------------- --------- ---------
Closing balance 21,803 -
---------------------------- --------- ---------
The investment in subsidiary undertakings is in the following
companies:
Name Country of incorporation Proportion of ownership Principal activities/status
interest
Cizzle Biotechnology Limited England and Wales 100% interest in ordinary Early detection of lung cancer
share capital
----------------------------- ------------------------ ----------------------------- ------------------------------
Cizzle Biotech Limited England and Wales 100% interest in ordinary Dormant
(formerly Enfis Limited) share capital
----------------------------- ------------------------ ----------------------------- ------------------------------
The registered address for ongoing subsidiaries is 6(th) floor,
60 Gracechurch Street, London, EC3V 0HR.
Cizzle Biotechnology Limited - as mentioned in Note 3, this
investment represents the value of the shares issued by the Company
in exchange for the entire share capital of CBL (GBP21,700,000 plus
stamp duty expenses of GBP103,000).
b. Intangible assets - Group and Company
Intangible assets represents the fair value an investment in a
royalty sharing arrangement with St George Street Capital ("SGSC"),
a UK-based medical charity. This agreement grants the Company
potential future royalty payments from the commercialisation of St
George Street's therapeutic asset AZD1656 of up to GBP5m, plus
potentially further payments from the use of a companion
diagnostic.
2021 2020
GBP'000 GBP'000
---------------------------- --------- ---------
Opening balance - -
Acquisition during the year 200 -
---------------------------- --------- ---------
Closing balance 200 -
---------------------------- --------- ---------
c. Tangible assets - Group
Laboratory
equipment Total
GBP'000 GBP'000
Cost
At 1 January 2021 - -
Acquired during the year 18 18
Write-off during the year (18) (18)
At 31 December 2021 - -
----------- ----------
Depreciation
At 1 January 2020 - -
Acquired during the year 18 18
Write-off during the year (18) (18)
At 31 December 2021 - -
----------- ----------
Net book value
At 31 December 2021 - -
=========== ==========
At 31 December 2020 - -
=========== ==========
On 14 May 2021 the Group acquired laboratory equipment with a
cost of GBP18,000 and a net book value of GBPNil. This equipment
was written off at 31 December 2021.
12 Trade and other receivables
Group CBL Company Company
2021 2020 2021 2020
GBP'000 GBP'000 GBP'000 GBP'000
----------------------------------- --------- --------- --------- ---------
Trade receivables - - - 4
Less: provision for impairment - - - -
----------------------------------- --------- --------- --------- ---------
Trade receivables (net) - - - 4
Amounts due from subsidiaries - - 216 -
Social security and other taxes 14 - 7 2
Corporation tax recoverable 37 - - -
Prepayments and other receivables 29 3 18 -
----------------------------------- --------- --------- --------- ---------
80 3 241 6
----------------------------------- --------- --------- --------- ---------
Trade and other receivables are non-derivative financial assets
with fixed or determinable payments that are not quoted in an
active market. They are classified as 'trade and other receivables'
in the statement of financial position and are included in current
assets, except for maturities greater than 12 months after the
statement of financial position date. These are classified as
non-current assets. The value of trade receivables shown above, in
addition to the value of cash balances on deposit with
counterparties (see Note 17), represents the Company's maximum
exposure to credit risk. No collateral is held as security.
Amounts due from subsidiary undertakings at 31 December 2021
represented net amounts provided to the Company's wholly owned
subsidiary, Cizzle Biotechnology Limited.
The fair value of trade and other receivables approximate to the
net book values stated above.
As of 31 December 2021, trade receivables of GBPNil (2020:
GBPNil) were past their due date of receipt.
Group CBL Company Company
2021 2020 2021 2020
GBP'000 GBP'000 GBP'000 GBP'000
----------------------- ---------- ---------- ---------- ---------
Up to two months past - - - -
due
Over two months past
due - - - 4
----------------------- ---------- ---------- ---------- ---------
As of 31 December 2021, trade receivables of GBPNil (2020:
GBPNil) were impaired. The individually impaired receivables relate
to balances where it has been assessed that the receivable is not
expected to be recovered.
13 Cash and cash equivalents
Group CBL Company Company
2021 2020 2021 2020
GBP'000 GBP'000 GBP'000 GBP'000
-------------------------------- --------- --------- --------- ---------
Cash on hand and balances with
banks 875 7 848 84
875 7 848 84
-------------------------------- --------- --------- --------- ---------
14 Share capital
Numbers in 000s
New Deferred Deferred
Ordinary 'A' shares 'A' shares
Shares
Nominal value per share 0.01p 0.01p 0.99p
At 31 December 2020 - - -
Recognition of PLC equity 24,817 225,158 12,383,626
Issued 228,631 - -
---------------------------- ---------------- -------------- ----------------
At 31 December 2021 253,448 225,158 12,383,626
---------------------------- ---------------- -------------- ----------------
The following table reconciles the
total nominal value of the shares
in issue:
New Deferred
Ordinary GBP0.01p Deferred
shares 'A' shares 'A' shares
Nominal value per share 0.01p 0.01p 0.99p Total
GBP000 GBP'000 GBP000 GBP000
At 31 December 2020 - - - -
On reverse takeover of Cizzle Biotechnology
Limited
* Recognition of PLC equity
1,238
-
* Consideration shares -
-
* Placing of shares for cash 3 2,229 3,470
21 - 21
2 - 2
* Settlement of fees - - -
--------------------------------------------- ---------- ------------ ------------ -----------
At 31 December 2021 26 1,238 2,229 3,493
--------------------------------------------- ---------- ------------ ------------ -----------
During the year ended 31 December 2021, the following shares
were issued:
No of shares Issue price
issued per share
14 May 2021 000s Pence
----------------------------------------- ------------- ------------
Reverse takeover - Cizzle Biotechnology
Ltd (non-cash) 206,311 10.0p
Placing (cash) 22,000 10.0p
Settlement of fees (non-cash) 320 10.0p
Total issued 228,631
-------------
On 14 May 2021 the Company issued investor warrants to subscribe
for 11,000,000 Ordinary Shares at a fixed price of 15p per share
valid for three years until 13 May 2024.
On 14 May 2021 the Company issued broker and adviser warrants to
subscribe for 1,350,000 Ordinary Shares at a fixed price of 10p per
share valid for three years until 13 May 2024. 250,000 of these
broker warrants are automatically exercisable upon the Company's
share price equalling 20p per share. The fair value of these
warrants at 31 December 2021 is GBP5,000 and has been accounted for
as a cost to the Company and a reduction of the share premium
account ( see statement of changes in equity on pages 37 to
38).
Employee share scheme
The Company has an Executive Share Option Scheme.
The exercise terms of all granted options as at 31 December 2021
are summarised below:
Date of grant Number of Exercise
options price (pence
per share) Exercise
dates from
--------------- ------------ -------------- -----------------------------
2015 300 5.02 2017
2016 800 1.85 2017
2017 500 1.00 2018
2021 3,689,096 1.53 2021
2021 19,741,345 10.00 2021 (based on performance)
--------------- ------------ -------------- -----------------------------
The number and weighted average exercise price of the options
that were exercisable at 31 December 2021 were 23,432,041 and 8.67p
respectively.
Movements in the number of share options outstanding and their
related weighted average exercise prices are as follows:
Average
exercise Options
price
(pence per number
share)
------------------------------ ----------- -----------
At 31 December 2020 -
Acquired on reverse takeover 1.53 3,690,696
Issued during year 10.00 19,741,345
------------------------------ ----------- -----------
At 31 December 2021 8.67 23,432,041
------------------------------ ----------- -----------
Share options outstanding at the end of the year have the
following expiry dates and exercise prices:
Exercise Options
Expiry date price 2021
(pence per
share)
--------------- ------------ -----------
2025 5.02 300
2026 1.85 800
2027 1.00 500
2027 1.53 3,689,096
2031 10.00 19,741,345
--------------- ------------ -----------
23,432,041
--------------- ------------ -----------
The Company determines the fair value of its share option
contracts on the grant date, adjusts this to reflect its
expectation of the options that will ultimately vest, and then
expenses the calculated balance on a straight-line basis through
its statement of comprehensive income over the expected vesting
period with a corresponding credit to its share option reserve.
Subsequent changes to the expectation of number of options that
will ultimately vest are dealt with prospectively such that the
cumulative amount charged to the statement of comprehensive income
is consistent with latest expectations. Subsequent changes in
market conditions do not impact the amount charged to the statement
of comprehensive income.
The Company determines the fair value of its share option
contracts using a model based on the Black-Scholes-Merton
methodology. In determining the fair value of its share option
contracts, the Company made the following assumptions (ranges are
provided where values differ across tranches). Expected volatility
was determined by reference to historical experience.
Grant Share Exercise Expected Expected Risk Fair
date Price Price Option Expected Dividend free Value
Pence Pence Life Volatility Yield Interest At date
Years % % Rate of
% Grant
Pence
2021 9.38p 1.53p 10 years 68% 0% 0.83% 1.60p
2021 4.40p 10.00p 10 years 32% 0% 0.83% 3.00p
15 Trade and other payables
Group CBL Company Company
2021 2020 2021 2020
GBP'000 GBP'000 GBP'000 GBP'000
--------------------------------- --------- --------- --------- ---------
Trade payables 111 2 73 14
Social security and other taxes 43 - 6 5
Accruals and other payables 64 6 54 39
--------------------------------- --------- --------- --------- ---------
218 8 133 58
--------------------------------- --------- --------- --------- ---------
Group CBL Company Company
2021 2020 2021 2020
GBP'000 GBP'000 GBP'000 GBP'000
---------------------------------- --------- --------- --------- ---------
Due or due in less than one
month 75 2 37 14
Due between one and three months 4 - 4 8
Due in more than three months 32 - 32 (8)
111 2 73 14
---------------------------------- --------- --------- --------- ---------
16 Borrowings
Group CBL Company Company
2021 2020 2021 2020
GBP'000 GBP'000 GBP'000 GBP'000
----------------------------- --------- --------- --------- ---------
Loans repayable in less than - 10 - -
one year
- 10 - -
----------------------------- --------- --------- --------- ---------
17 Financial assets and liabilities
The tables below analyse the carrying value of financial assets
and financial liabilities in the Group's and Company's statements
of financial position. Further information on the classes that make
up each category is provided in the notes indicated. The carrying
value of each category is considered a reasonable approximation of
its fair value. All amounts are due within one year.
Group CBL Company Company
2021 2020 2021 2020
GBP'000 GBP'000 GBP'000 GBP'000
----------------------------------- --------- --------- --------- ---------
Trade receivables (Note 12) - - - 4
Amounts due from subsidiaries - - 216 -
(Note 12)
Prepayments and other receivables
(Note 12) 29 3 18 -
Cash and cash equivalents (Note
13) 875 7 848 84
----------------------------------- --------- --------- --------- ---------
Financial assets at amortised
cost 904 10 1,082 88
----------------------------------- --------- --------- --------- ---------
Group CBL Company Company
2021 2020 2021 2020
GBP'000 GBP'000 GBP'000 GBP'000
------------------------------------ --------- --------- --------- ---------
Trade payables (Note 15) 111 2 73 22
Accruals and other payables
(Note 15) 64 6 54 36
Borrowings (Note 16) - 10 - -
------------------------------------ --------- --------- --------- ---------
Financial liabilities at amortised
cost 175 18 127 58
------------------------------------ --------- --------- --------- ---------
18 Deferred income tax
There is an un-provided deferred tax asset arising on taxable
losses of GBP0.47m (2020: GBP0.2m). In accordance with accounting
standards, the deferred tax asset has not been recognised in the
financial statements due to uncertainty over the availability of
sufficient future profits against which it could be recovered.
At 31 December 2021 there was no deferred tax liability (2020:
GBPnil).
19 Commitments
The Group has no commitments as at 31 December 2021 (2020:
GBPNil).
20 Related party transactions
Transactions with directors
Directors' emoluments as noted in note 8. The Group's Statement
of Comprehensive Income includes an amount of GBP7,366 (2020:
GBP20,000) paid to Experience Capital Limited in respect of
non-executive director services provided by Martin Lampshire.
21 Controlling party
The directors consider there to be no ultimate controlling
party.
22 Capital management
In managing its capital structure, the Company's objective is to
safeguard the Company's ability to continue as a going concern,
managing cash flows so that it can continue to provide returns for
shareholders.
The Company makes adjustments to its capital structure in the
light of changes in economic conditions and the requirements of the
Company's businesses. The Board has sought to maintain low levels
of borrowing to reflect the development stage of the Company's
businesses. Over time as the Company's businesses mature and become
profitable the Board is likely to make increased use of borrowing
facilities to fund working capital. In order to maintain or adjust
the capital structure, the Company may issue new shares or seek
additional borrowing facilities. The Company monitors capital on
several bases including the debt to equity ratio. This ratio is
calculated as debt ÷ equity. Debt is calculated as total borrowings
as shown in the consolidated statement of financial position.
Equity comprises all components of equity as shown in the
consolidated statement of financial position. The debt-to-equity
ratio at 31 December 2021 and 31 December 2020 was as follows:
Group CBL Company Company
2021 2020 2021 2020
GBP'000 GBP'000 GBP'000 GBP'000
---------------------- --------- --------- --------- ---------
Total debt - 10 - -
Total equity 937 (8) 22,959 32
Debt-to-equity ratio 0.0% 125% 0.0% 0.0%
---------------------- --------- --------- --------- ---------
23 Reserves
The following reserves describe the nature and purpose of each
reserve within equity:
a. Capital reduction reserve
The capital reduction reserve set out in the Statement of
Changes in Equity arose in 2014 when the nominal value of each
share was reduced from 10p to 1p.
b. Share premium
The amount subscribed for each share in excess of nominal
value.
c. Reverse acquisition reserve
The reverse acquisition reserve is explained in Note 3.
d. Share option
The accumulated expense arising during their vesting period of
share options granted to directors and employees and warrants
granted to third parties.
e. Accumulated losses
All other net losses and gains not recognised elsewhere.
24 Subsequent events
a) Royalty Investment in AZD 1656
On 14 February 2022 it was announced that the Company had
entered into a definitive agreement (the "Agreement") with Conduit
Pharmaceuticals Limited ("Conduit") and St George Street Capital
Limited ("SGSC") to acquire a 5% economic interest in the
commercialisation of the AZD 1656 asset or other such assets being
developed by Conduit or SGSC to treat inflammatory pulmonary and
cardiovascular disease (the "Economic Interest").
Highlights of the Agreement are as follows:
- Agreement with Conduit and SGSC to acquire a 5% economic
interest for a total consideration of GBP1.88 million,
to be settled in new Cizzle ordinary shares at a price
of 4.0p per share, a 56.9% premium to the closing mid-market
price on 11 February 2022;
- The Agreement is in addition to the Company's existing
interest in AZD 1656 as announced on 20 September 2021:
- SGSC recently reported the successful completion of the
AZD 1656 ARCADIA clinical trial in Covid-19 and SGSC
and Conduit are in discussions with multiple pharmaceutical
companies about licensing opportunities for AZD 1656
for Covid-19 and potentially for further indications;
and
- The Agreement supports the Company's ambitions to expand
its target customer base into the pharmaceutical industry
and is in line with its strategy of building a portfolio
of early cancer detection tests, companion diagnostics
and royalty bearing stakes in significant drug assets.
Consideration for the Agreement
Under the terms of the Agreement, Cizzle will pay consideration
of GBP1.88 million to SGS for the Economic Interest. Of the
consideration payable, GBP1.0 million (the "Initial Consideration")
will be satisfied by the issue of 25,000,000 new ordinary shares in
the Company (the "Consideration Shares"), at a price of 4.0 pence
per Consideration Share, being a premium of 56.9 per cent. to the
Company's closing mid-market price of 2.55 pence on 11 February
2022. The remaining consideration of GBP880,000 will be payable in
new ordinary shares in the Company issued at 4.0 pence per share,
on the earlier of receiving shareholder approval to issue the
shares or the first anniversary of completion.
The transaction is considered to be a non-adjusting subsequent
event as the decision to make this investment was not undertaken
until just prior to the announcement. In 2022 the Group intends to
account for this investment within intangible assets.
b) USA
On 6 May 2022 the Group announced that it had signed a heads of
terms to partner with CorePath Laboratories (CorePath), a full
service cancer reference laboratory, to develop and offer its
proprietary early-stage lung cancer test throughout the USA. The
proposal is that the Group would receive a 15% royalty and royalty
sharing arrangements overall offering of products and services
using CIZ1B via CorePath in the USA.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
FR SEWESUEESESI
(END) Dow Jones Newswires
May 30, 2022 02:01 ET (06:01 GMT)
Cizzle Biotechnology (LSE:CIZ)
Historical Stock Chart
From Apr 2024 to May 2024
Cizzle Biotechnology (LSE:CIZ)
Historical Stock Chart
From May 2023 to May 2024